• Risks to health and environment are evaluated in a pre-market evaluation. • Not all uses of products can be evaluated, especially if they change over time. • In a post-market evaluation new data may change the perspective. • Population-based observational studies include effects of product co-formulants. • For some products such data could lead to the decision to further restrict use.
No takes yet. Share an insight, caveat, or question.
Scheepers et al. (2019) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: